

Richard B Lipton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8450808/publications.pdf>

Version: 2024-02-01

458
papers

29,574
citations

6124

83
h-index

7836

155
g-index

547
all docs

547
docs citations

547
times ranked

21989
citing authors

#	ARTICLE	IF	CITATIONS
1	Measuring headache day severity using multiple features in daily diary designs. <i>Cephalalgia</i> , 2022, 42, 53-62.	1.8	4
2	Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial. <i>Cephalalgia</i> , 2022, 42, 3-11.	1.8	29
3	Reliabilities of Intra-Individual Mean and Intra-Individual Variability of Self-Reported Pain Derived From Ecological Momentary Assessments: Results From the Einstein Aging Study. <i>Journal of Pain</i> , 2022, 23, 616-624.	0.7	4
4	Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study. <i>Headache</i> , 2022, 62, 122-140.	1.8	43
5	Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials. <i>Headache</i> , 2022, 62, 159-168.	1.8	1
6	Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials. <i>Journal of Headache and Pain</i> , 2022, 23, 23.	1.8	4
7	Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study. <i>Journal of Headache and Pain</i> , 2022, 23, 22.	2.5	7
8	Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI. <i>Neurology</i> , 2022, 98, .	1.5	10
9	Do behavioral treatments work for migraine prevention?. <i>Headache</i> , 2022, 62, 402-404.	1.8	2
10	Impact of the COVID-19 pandemic on people living with migraine: Results of the MiCOAS qualitative study. <i>Headache</i> , 2022, 62, 284-293.	1.8	11
11	Longitudinal associations between falls and future risk of cognitive decline, the Motoric Cognitive Risk syndrome and dementia: the Einstein Ageing Study. <i>Age and Ageing</i> , 2022, 51, .	0.7	11
12	Dose-response relationship between late-life physical activity and incident dementia: A pooled analysis of 10 cohort studies of memory in an international consortium. <i>Alzheimer's and Dementia</i> , 2022, .	0.4	8
13	Real-world assessment of the relationship between migraine-related disability and healthcare costs in the United States. <i>Headache</i> , 2022, 62, 473-481.	1.8	11
14	Individuals with both higher recent negative affect and physical pain have higher levels of C-reactive protein. <i>Brain, Behavior, & Immunity - Health</i> , 2022, 21, 100431.	1.3	4
15	Development and validation of a novel patient-reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary. <i>Headache</i> , 2022, 62, 89-105.	1.8	12
16	Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE for research in migraine prevention. <i>Headache</i> , 2022, 62, 690-699.	1.8	6
17	Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis. <i>Pain and Therapy</i> , 2022, 11, 701-712.	1.5	6
18	Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials. <i>Journal of Headache and Pain</i> , 2022, 23, 50.	2.5	6

#	ARTICLE	IF	CITATIONS
19	Predicting Amyloid Positivity in Cognitively Unimpaired Older Adults. <i>Neurology</i> , 2022, 98, .	1.5	7
20	Psychiatric Sequelae Following Whiplash Injury: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2022, 13, 814079.	1.3	3
21	Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials. <i>Journal of Medical Economics</i> , 2022, 25, 630-639.	1.0	4
22	Predictive models for determining treatment response to nonprescription acute medications in migraine: Results from the American Migraine Prevalence and Prevention Study. <i>Headache</i> , 2022, 62, 755-765.	1.8	5
23	Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1 st edition. <i>Cephalalgia</i> , 2022, 42, 1099-1115.	1.8	5
24	Concordance Between Self-Reported Medical Diagnosis of Mild Cognitive Impairment/Dementia and Neurocognitive Function Among Middle-Aged and Older Hispanic/Latino Adults: Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) and the Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA). <i>Journal of Alzheimer's Disease</i> , 2022, , 1-11.	1.2	0
25	O322 sleep disordered breathing and MRI markers of brain aging in the Hispanic Community Health Study/Study of Latinos. <i>Sleep</i> , 2022, 45, A145-A145.	0.6	0
26	2021... OnabotA for CM: benefits beyond headache-day reduction. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A73.1-A73.	0.9	0
27	Association of Mediterranean Diet With Cognitive Decline Among Diverse Hispanic or Latino Adults From the Hispanic Community Health Study/Study of Latinos. <i>JAMA Network Open</i> , 2022, 5, e2221982.	2.8	17
28	Factors associated with hospitalization for ischemic stroke and TIA following an emergency department headache visit. <i>American Journal of Emergency Medicine</i> , 2021, 46, 503-507.	0.7	4
29	A Coordinated Multi-study Analysis of the Longitudinal Association Between Handgrip Strength and Cognitive Function in Older Adults. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2021, 76, 229-241.	2.4	43
30	Framing potential for adverse effects of repetitive subconcussive impacts in soccer in the context of athlete and non-athlete controls. <i>Brain Imaging and Behavior</i> , 2021, 15, 882-895.	1.1	12
31	Patterns of Perceived Stress Throughout the Migraine Cycle: A Longitudinal Cohort Study Using Daily Prospective Diary Data. <i>Headache</i> , 2021, 61, 90-102.	1.8	14
32	Headache complexity (number of symptom features) differentiates post-traumatic from non-traumatic headaches. <i>Cephalalgia</i> , 2021, 41, 582-592.	1.8	3
33	Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension. <i>Cephalalgia</i> , 2021, 41, 6-16.	1.8	25
34	Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study. <i>Headache</i> , 2021, 61, 103-116.	1.8	10
35	Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2021, 397, 51-60.	6.3	178
36	Reliability and validity of the 6-item Headache Impact Test in chronic migraine from the PROMISE-2 study. <i>Quality of Life Research</i> , 2021, 30, 931-943.	1.5	14

#	ARTICLE	IF	CITATIONS
37	Mentally Challenging Occupations Are Associated With More Rapid Cognitive Decline at Later Stages of Cognitive Aging. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2021, 76, 671-680.	2.4	10
38	Stress Is Associated With Neurocognitive Function in Hispanic/Latino Adults: Results From HCHS/SOL Socio-Cultural Ancillary Study. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2021, 76, e122-e128.	2.4	12
39	Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society. <i>Cephalalgia</i> , 2021, 41, 279-293.	1.8	24
40	Evaluation of the 6-item Identify Chronic Migraine screener in a large medical group. <i>Headache</i> , 2021, 61, 335-342.	1.8	5
41	Underuse of Behavioral Treatments for Headache: a Narrative Review Examining Societal and Cultural Factors. <i>Journal of General Internal Medicine</i> , 2021, 36, 3103-3112.	1.3	13
42	Systematic review of outcomes and endpoints in preventive migraine clinical trials. <i>Headache</i> , 2021, 61, 253-262.	1.8	28
43	Between and within-woman differences in the association between menstruation and migraine days. <i>Headache</i> , 2021, 61, 430-437.	1.8	5
44	Acute Treatment of Migraine with Celecoxib Oral Solution: Results of a Randomized, Placebo-Controlled Clinical Trial. <i>Journal of Pain Research</i> , 2021, Volume 14, 549-560.	0.8	3
45	Systematic review of outcomes and endpoints in acute migraine clinical trials. <i>Headache</i> , 2021, 61, 263-275.	1.8	33
46	Re-evaluation of psychometric evidence and update of normative data for the Test of Practical Judgment. <i>Clinical Neuropsychologist</i> , 2021, , 1-24.	1.5	3
47	Tension-type headache. <i>Nature Reviews Disease Primers</i> , 2021, 7, 24.	18.1	75
48	Abstract P257: Cost-Effectiveness of Advanced Neuroimaging for Transient & Minor Neurological Events in the Emergency Department. <i>Stroke</i> , 2021, 52, .	1.0	0
49	Introduction of a smartphone based behavioral intervention for migraine in the emergency department. <i>General Hospital Psychiatry</i> , 2021, 69, 12-19.	1.2	8
50	Migraine: epidemiology and systems of care. <i>Lancet, The</i> , 2021, 397, 1485-1495.	6.3	310
51	Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study. <i>Headache</i> , 2021, 61, 628-641.	1.8	35
52	Author Response: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study. <i>Neurology</i> , 2021, 96, 683-684.	1.5	1
53	Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study. <i>Headache</i> , 2021, 61, 662-672.	1.8	27
54	Author Response: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study. <i>Neurology</i> , 2021, 96, 686-686.	1.5	1

#	ARTICLE	IF	CITATIONS
55	Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study. <i>Headache</i> , 2021, 61, 642-652.	1.8	37
56	Author Response: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study. <i>Neurology</i> , 2021, 96, 684-685.	1.5	0
57	A coordinated analysis of the associations among personality traits, cognitive decline, and dementia in older adulthood. <i>Journal of Research in Personality</i> , 2021, 92, 104100.	0.9	17
58	Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II. <i>Cephalalgia</i> , 2021, 41, 979-990.	1.8	19
59	White matter hyperintensities and cognition across different Alzheimer's biomarker profiles. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1906-1915.	1.3	14
60	Naturalistic assessment of patterns and predictors of acute headache medication use among women with comorbid migraine and overweight or obesity. <i>Translational Behavioral Medicine</i> , 2021, 11, 1495-1506.	1.2	0
61	Development and psychometric evaluation of the Test of Practical Judgment alternate form (Form B). <i>Applied Neuropsychology Adult</i> , 2021, , 1-10.	0.7	1
62	Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome. <i>Headache</i> , 2021, 61, 766-776.	1.8	20
63	Potassium channel openers – novel triggers of aura and migraine. <i>Nature Reviews Neurology</i> , 2021, 17, 397-398.	4.9	5
64	Efficacy of erenumab in chronic migraine patients with and without ictal allodynia. <i>Cephalalgia</i> , 2021, 41, 1152-1160.	1.8	10
65	Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. <i>Headache</i> , 2021, 61, 992-1003.	1.8	44
66	Learning the full impact of migraine through patient voices: A qualitative study. <i>Headache</i> , 2021, 61, 1004-1020.	1.8	24
67	The value of the patient perspective in understanding the full burden of migraine. <i>Headache</i> , 2021, 61, 985-987.	1.8	1
68	Psychiatric and cognitive comorbidities of persistent post-traumatic headache attributed to mild traumatic brain injury. <i>Journal of Headache and Pain</i> , 2021, 22, 83.	2.5	26
69	Trajectories of frailty in aging: Prospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0253976.	1.1	12
70	Prevalence of incidental brain MRI findings of clinical relevance in a diverse Hispanic/Latino population. <i>Journal of Neuroimaging</i> , 2021, 31, 1166-1175.	1.0	2
71	Cerebrovascular disease hospitalizations following emergency department headache visits: A nested case-control study. <i>Academic Emergency Medicine</i> , 2021, , .	0.8	5
72	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Tolerability, and Safety of Celecoxib Oral Solution (ELYXYB) in Acute Treatment of Episodic Migraine with or without Aura. <i>Journal of Pain Research</i> , 2021, Volume 14, 2529-2542.	0.8	6

#	ARTICLE	IF	CITATIONS
73	What do people want to know about "Growing Up with Migraine"? Results of a preference survey of people with lived experience to guide future research. <i>Cephalalgia</i> , 2021, , 033310242110385.	1.8	1
74	Atogepant for the Preventive Treatment of Migraine. <i>New England Journal of Medicine</i> , 2021, 385, 695-706.	13.9	126
75	Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies. <i>Cephalalgia</i> , 2021, 41, 033310242110289.	1.8	3
76	A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN. <i>Journal of Headache and Pain</i> , 2021, 22, 101.	2.5	3
77	Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant. <i>Advances in Therapy</i> , 2021, 38, 5209-5220.	1.3	9
78	UDSNB 3.0 Neuropsychological Test Norms in Older Adults from a Diverse Community: Results from the Einstein Aging Study (EAS). <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1665-1678.	1.2	7
79	Latent Cognitive Class at Enrollment Predicts Future Cognitive Trajectories of Decline in a Community Sample of Older Adults. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 641-652.	1.2	1
80	A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adults. <i>Cephalalgia Reports</i> , 2021, 4, 251581632110079.	0.2	6
81	Psychosocial Factors Associated with Cognitive Function Among Middle-Aged and Older Hispanics/Latinos: The Hispanic Community Health Study/Study of Latinos and its Sociocultural Ancillary Study. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 433-449.	1.2	13
82	Health-related quality of life in tension-type headache: a population-based study. <i>Scandinavian Journal of Pain</i> , 2021, 21, 778-787.	0.5	12
83	Medication Overuse and Headache Burden. <i>Neurology: Clinical Practice</i> , 2021, 11, 216-226.	0.8	25
84	The migraine signature study: Methods and baseline results. <i>Headache</i> , 2021, 61, 462-484.	1.8	7
85	Head Computed tomography during emergency department treat-and-release visit for headache is associated with increased risk of subsequent cerebrovascular disease hospitalization. <i>Diagnosis</i> , 2021, 8, 199-208.	1.2	8
86	Under Treatment of High-Risk TIA Patients with Clopidogrel-Aspirin in the Emergency Setting. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 106145.	0.7	1
87	Leveraging machine learning predictive biomarkers to augment the statistical power of clinical trials with baseline magnetic resonance imaging. <i>Brain Communications</i> , 2021, 3, fcab264.	1.5	5
88	Response to Mindfulness-Based Cognitive Therapy Differs Between Chronic and Episodic Migraine. <i>Neurology: Clinical Practice</i> , 2021, 11, 194-205.	0.8	6
89	Core outcome set for preventive intervention trials in chronic and episodic migraine (COSMIG): an international, consensus-derived and multistakeholder initiative. <i>BMJ Open</i> , 2021, 11, e043242.	0.8	18
90	Emergency medicine physicians'™ perspectives on diagnostic accuracy in neurology: a qualitative study. <i>Diagnosis</i> , 2021, .	1.2	1

#	ARTICLE	IF	CITATIONS
91	Variability in Cognitive Performance on Mobile Devices Is Sensitive to Mild Cognitive Impairment: Results From the Einstein Aging Study. <i>Frontiers in Digital Health</i> , 2021, 3, 758031.	1.5	25
92	Reliabilities of mean and variability of ambulatory pain among community dwelling older adults. <i>Innovation in Aging</i> , 2021, 5, 885-885.	0.0	0
93	Combining patient reported outcomes and EHR data to understand population level treatment needs: correcting for selection bias in the migraine signature study. <i>Journal of Patient-Reported Outcomes</i> , 2021, 5, 132.	0.9	3
94	Increases in Neuroticism May Be an Early Indicator of Dementia: A Coordinated Analysis. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2020, 75, 251-262.	2.4	19
95	Detecting biological heterogeneity patterns in ADNI amnesic mild cognitive impairment based on volumetric MRI. <i>Brain Imaging and Behavior</i> , 2020, 14, 1792-1804.	1.1	24
96	Proposed new diagnostic criteria for chronic migraine. <i>Cephalalgia</i> , 2020, 40, 399-406.	1.8	50
97	Efficacy, Tolerability, and Safety of DFNâ€15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Doubleâ€Blind, Placeboâ€Controlled Study. <i>Headache</i> , 2020, 60, 58-70.	1.8	14
98	Predicting Amyloid-Î² Levels in Amnesic Mild Cognitive Impairment Using Machine Learning Techniques. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1211-1219.	1.2	27
99	Predicting dementia with routine care EMR data. <i>Artificial Intelligence in Medicine</i> , 2020, 102, 101771.	3.8	38
100	Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study. <i>Headache</i> , 2020, 60, 416-429.	1.8	61
101	Passive Digital Signature for Early Identification of Alzheimer's Disease and Related Dementia. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 511-518.	1.3	15
102	Focus group findings on the migraine patient experience during research studies and ideas for future investigations. <i>Cephalalgia</i> , 2020, 40, 712-734.	1.8	14
103	Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis. <i>Pain and Therapy</i> , 2020, 9, 683-694.	1.5	3
104	Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2020, 60, 2340-2356.	1.8	47
105	Education and the moderating roles of age, sex, ethnicity and apolipoprotein epsilon 4 on the risk of cognitive impairment. <i>Archives of Gerontology and Geriatrics</i> , 2020, 91, 104112.	1.4	6
106	Interrelations between migraine-like headache and persistent post-traumatic headache attributed to mild traumatic brain injury: a prospective diary study. <i>Journal of Headache and Pain</i> , 2020, 21, 134.	2.5	17
107	Smartphoneâ€Delivered Progressive Muscle Relaxation for the Treatment of Migraine in Primary Care: A Randomized Controlled Trial. <i>Headache</i> , 2020, 60, 2232-2246.	1.8	30
108	Predicting the Future of Migraine Attack Prediction. <i>Headache</i> , 2020, 60, 2125-2128.	1.8	4

#	ARTICLE	IF	CITATIONS
109	The Effect of Psychiatric Comorbidities on Headache-Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i> , 2020, 60, 1683-1696.	1.8	42
110	Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study. <i>Headache</i> , 2020, 60, 2444-2453.	1.8	13
111	Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. <i>Cephalalgia</i> , 2020, 40, 1026-1044.	1.8	105
112	The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine. <i>Pain and Therapy</i> , 2020, 9, 695-707.	1.5	3
113	Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic Migraine. <i>Headache</i> , 2020, 60, 2003-2013.	1.8	22
114	Cognition and Daily Functioning: Results from the Hispanic Community Health Study/Study of Latinos (SOL) and Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA). <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1267-1278.	1.2	7
115	Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine. <i>Headache</i> , 2020, 60, 1734-1742.	1.8	54
116	Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data. <i>Journal of Primary Care and Community Health</i> , 2020, 11, 215013272096368.	1.0	24
117	Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 167.	3.0	64
118	Variability in working memory performance on mobile devices is sensitive to mild cognitive impairment: Results from the Einstein Aging Study. <i>Alzheimer's and Dementia</i> , 2020, 16, e039960.	0.4	0
119	Prediction of longitudinal clinical outcomes of MCI population using Alzheimer's AT[N] biomarker profiling: Can machine learning methods improve our predictions?. <i>Alzheimer's and Dementia</i> , 2020, 16, e041125.	0.4	0
120	Cognitive leisure activities in later older adulthood may protect against accelerated rates of memory decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e041512.	0.4	1
121	Daily functioning and cognition: Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) and Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA). <i>Alzheimer's and Dementia</i> , 2020, 16, e044165.	0.4	0
122	Cardiovascular and stroke risk, cognitive change, and mild cognitive impairment: Results from the HCHS/SOL and SOL-INCA. <i>Alzheimer's and Dementia</i> , 2020, 16, e044166.	0.4	0
123	Subjective cognitive decline is associated with neurocognition in the SOL-INCA study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044167.	0.4	0
124	Optimizing the memory binding test for detection of aMCI and dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e044596.	0.4	0
125	Diabetes, cognitive decline and mild cognitive impairment among diverse Hispanics/Latinos: Hispanic Community Health Study/Study of Latinos (HCHS-SOL) investigation of cognitive aging results. <i>Alzheimer's and Dementia</i> , 2020, 16, e044601.	0.4	1
126	Comparing versions of the memory binding test: Predictive validity for incident aMCI and incident dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e044612.	0.4	0

#	ARTICLE	IF	CITATIONS
127	Cumulative effects of sleep quality on risk for incident mild cognitive impairment (MCI): Results from the Einstein Aging Study (EAS) cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e044861.	0.4	0
128	Variability in every day pain is associated with mild cognitive impairment (MCI): Results from the Einstein Aging Study (EAS). <i>Alzheimer's and Dementia</i> , 2020, 16, e045355.	0.4	1
129	Dizziness and vertigo during the prodromal phase and headache phase of migraine: A systematic review and meta-analysis. <i>Cephalalgia</i> , 2020, 40, 1095-1103.	1.8	16
130	Neck pain and headache after whiplash injury: a systematic review and meta-analysis. <i>Pain</i> , 2020, 161, 880-888.	2.0	22
131	A Latent Transition Analysis Model to Assess Change in Cognitive States over Three Occasions: Results from the Rush Memory and Aging Project. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1063-1073.	1.2	6
132	Evolution of the Research Literature and the Scientific Community of Alzheimer's Disease from 1983-2017: A 35-Year Survey. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 1105-1134.	1.2	2
133	Post-Traumatic Stress Disorder After Traumatic Brain Injury: A Systematic Review and Meta-Analysis. <i>Neurological Sciences</i> , 2020, 41, 2737-2746.	0.9	29
134	Effect of Mentally Challenging Occupations on Incident Dementia Differs Between African Americans and Non-Hispanic Whites. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 1405-1416.	1.2	1
135	Trajectories of Big Five Personality Traits: A Coordinated Analysis of 16 Longitudinal Samples. <i>European Journal of Personality</i> , 2020, 34, 301-321.	1.9	74
136	APOE ϵ 4 and the Influence of Sex, Age, Vascular Risk Factors, and Ethnicity on Cognitive Decline. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 1863-1873.	1.7	23
137	Characterizing opioid use in a US population with migraine. <i>Neurology</i> , 2020, 95, e457-e468.	1.5	48
138	Testing rimegepant for migraine: time to revise the trial design? "Authors' reply. <i>Lancet, The</i> , 2020, 395, 1901-1902.	6.3	1
139	Acute treatment patterns in patients with migraine newly initiating a triptan. <i>Cephalalgia</i> , 2020, 40, 437-447.	1.8	13
140	Efficacy and safety of eptinezumab in patients with chronic migraine. <i>Neurology</i> , 2020, 94, e1365-e1377.	1.5	236
141	Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response. <i>Cephalalgia</i> , 2020, 40, 639-649.	1.8	19
142	Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. <i>Journal of Headache and Pain</i> , 2020, 21, 23.	2.5	143
143	Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study. <i>Journal of Headache and Pain</i> , 2020, 21, 20.	2.5	35
144	Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II. <i>Headache</i> , 2020, 60, 686-700.	1.8	45

#	ARTICLE	IF	CITATIONS
145	Associations of Apolipoprotein E ϵ 4 Genotype and Ball Heading With Verbal Memory in Amateur Soccer Players. <i>JAMA Neurology</i> , 2020, 77, 419.	4.5	19
146	Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. <i>Neurology</i> , 2020, 94, e2121-e2125.	1.5	60
147	Characterization of Acute Prescription Migraine Medication Use. <i>Mayo Clinic Proceedings</i> , 2020, 95, 709-718.	1.4	14
148	Diabetes, Cognitive Decline, and Mild Cognitive Impairment Among Diverse Hispanics/Latinos: Study of Latinos—Investigation of Neurocognitive Aging Results (HCHS/SOL). <i>Diabetes Care</i> , 2020, 43, 1111-1117.	4.3	24
149	Is Healthy Neuroticism Associated with Longevity? A Coordinated Integrative Data Analysis. <i>Collabra: Psychology</i> , 2020, 6, .	0.9	14
150	Is it time to use predictive models to boost power of Alzheimer's disease clinical trials? A post hoc analysis of phase 3 solanezumab trials. <i>Alzheimer's and Dementia</i> , 2020, 16, e043022.	0.4	0
151	Evaluating Daily Versus Global Stress Appraisals' Sensitivity to Mild Cognitive Impairment. <i>Innovation in Aging</i> , 2020, 4, 598-599.	0.0	0
152	Activity Diversity in Detecting Ambulatory Cognitive Deficits. <i>Innovation in Aging</i> , 2020, 4, 599-599.	0.0	0
153	Treatment Patterns and Unmet Needs in the Acute Treatment of Migraine. <i>Journal of Family Practice</i> , 2020, 69, S1-S7.	0.2	0
154	A Gray Matter Volume Covariance Network Associated with the Motoric Cognitive Risk Syndrome: A Multicohort MRI Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 884-889.	1.7	53
155	Epidemiology of migraine in men: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Cephalalgia</i> , 2019, 39, 296-305.	1.8	34
156	Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i> , 2019, 59, 1286-1299.	1.8	135
157	Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study. <i>Headache</i> , 2019, 59, 1310-1323.	1.8	54
158	Estimation of multi-state models with missing covariate values based on observed data likelihood. <i>Communications in Statistics - Theory and Methods</i> , 2019, 48, 5733-5747.	0.6	0
159	Neuropsychological latent classes at enrollment and postmortem neuropathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 1195-1207.	0.4	8
160	Migraine Progression: A Systematic Review. An Editorial Comment. <i>Headache</i> , 2019, 59, 974-976.	1.8	3
161	Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2019, 394, 737-745.	6.3	236
162	Two randomized migraine studies of galcanezumab. <i>Neurology</i> , 2019, 93, e508-e517.	1.5	24

#	ARTICLE	IF	CITATIONS
163	Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. <i>New England Journal of Medicine</i> , 2019, 381, 142-149.	13.9	235
164	Determinants of cognitive performance and decline in 20 diverse ethno-regional groups: A COSMIC collaboration cohort study. <i>PLoS Medicine</i> , 2019, 16, e1002853.	3.9	86
165	A Birth Cohort Analysis of Amnesic Mild Cognitive Impairment Incidence in the Einstein Aging Study (EAS) Cohort. <i>Journal of Alzheimer's Disease</i> , 2019, 70, S271-S281.	1.2	6
166	Anxiety sensitivity and intentional avoidance of physical activity in women with probable migraine. <i>Cephalalgia</i> , 2019, 39, 1465-1469.	1.8	16
167	Assessing diagnostic error in cerebral venous thrombosis via detailed chart review. <i>Diagnosis</i> , 2019, 6, 361-367.	1.2	7
168	Sex-specific norms for verbal memory tests may improve diagnostic accuracy of amnesic MCI. <i>Neurology</i> , 2019, 93, e1881-e1889.	1.5	59
169	Migraine. <i>Neurologic Clinics</i> , 2019, 37, 631-649.	0.8	358
170	Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 171.	1.0	6
171	Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i> , 2019, 59, 1762-1772.	1.8	31
172	FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine. <i>Headache</i> , 2019, 59, 1700-1713.	1.8	55
173	Does Mindfulness-Based Cognitive Therapy for Migraine Reduce Migraine-Related Disability in People with Episodic and Chronic Migraine? A Phase 2b Pilot Randomized Clinical Trial. <i>Headache</i> , 2019, 59, 1448-1467.	1.8	62
174	Optimizing Machine Learning Methods to Improve Predictive Models of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 1027-1036.	1.2	26
175	The Independent and Interactive Associations of Bilingualism and Sex on Cognitive Performance in Hispanics/Latinos of the Hispanic Community Health Study/Study of Latinos. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 1271-1283.	1.2	9
176	Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study. <i>Journal of Headache and Pain</i> , 2019, 20, 10.	2.5	18
177	Migraine day frequency in migraine prevention: longitudinal modelling approaches. <i>BMC Medical Research Methodology</i> , 2019, 19, 20.	1.4	8
178	Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. <i>Cephalalgia</i> , 2019, 39, 1075-1085.	1.8	107
179	Anxiety Sensitivity as a Risk Indicator for Anxiety, Depression, and Headache Severity in Women With Migraine. <i>Headache</i> , 2019, 59, 1212-1220.	1.8	9
180	Pathophysiology, prevention, and treatment of medication overuse headache. <i>Lancet Neurology</i> , The, 2019, 18, 891-902.	4.9	151

#	ARTICLE	IF	CITATIONS
181	Motoric cognitive risk syndrome and predictors of transition to dementia: A multicenter study. <i>Alzheimer's and Dementia</i> , 2019, 15, 870-877.	0.4	45
182	Cardiovascular disease risk factor burden and cognition: Implications of ethnic diversity within the Hispanic Community Health Study/Study of Latinos. <i>PLoS ONE</i> , 2019, 14, e0215378.	1.1	21
183	Spotlight on headache. <i>Neurology: Clinical Practice</i> , 2019, 9, 182-182.	0.8	0
184	The relationship between hippocampal volume, chronic pain, and depressive symptoms in older adults. <i>Psychiatry Research - Neuroimaging</i> , 2019, 289, 10-12.	0.9	14
185	Evaluating Mean Level and Within-Person Consistency in Migraine Pain Intensity and Migraine-Related Disability for AVP-825 vs Oral Sumatriptan: Results from the COMPASS Study, A Randomized Trial. <i>Headache</i> , 2019, 59, 1002-1013.	1.8	7
186	Erenumab in chronic migraine. <i>Neurology</i> , 2019, 92, e2250-e2260.	1.5	83
187	A Multi-study Coordinated Meta-analysis of Pulmonary Function and Cognition in Aging. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1793-1804.	1.7	20
188	Relationship Between Treatment Initiation and Healthcare Costs in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1575-1585.	1.2	7
189	Development of a claims-based algorithm to identify potentially undiagnosed chronic migraine patients. <i>Cephalalgia</i> , 2019, 39, 465-476.	1.8	12
190	Psychometric Validation of the Role Function Restrictive Domain of the Migraine Specific Quality-of-Life Questionnaire Version 2.1 Electronic Patient-Reported Outcome in Patients With Episodic and Chronic Migraine. <i>Headache</i> , 2019, 59, 756-774.	1.8	14
191	DFN-02, Sumatriptan 10mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment. <i>CNS Drugs</i> , 2019, 33, 375-382.	2.7	6
192	Naproxen for presymptomatic Alzheimer disease. <i>Neurology</i> , 2019, 92, 829-830.	1.5	11
193	The Temporal Relationship between Pain Intensity and Pain Interference and Incident Dementia. <i>Current Alzheimer Research</i> , 2019, 16, 109-115.	0.7	44
194	Predictors of allodynia in persons with migraine: Results from the Migraine in America Symptoms and Treatment (MAST) study. <i>Cephalalgia</i> , 2019, 39, 873-882.	1.8	26
195	Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. <i>Cephalalgia</i> , 2019, 39, 687-710.	1.8	154
196	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates APOE, tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	9.4	1,962
197	Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study. <i>Journal of Headache and Pain</i> , 2019, 20, 12.	2.5	16
198	AFFECTIONATE PHYSICAL TOUCH MITIGATES PAIN AND EMOTIONAL DISTRESS IN OLDER ADULTS. <i>Innovation in Aging</i> , 2019, 3, S810-S810.	0.0	0

#	ARTICLE	IF	CITATIONS
199	THE APOE- ϵ 4 ALLELE AND AGE SYNERGISTICALLY DRIVE DISEASE PROGRESSION IN ALZHEIMER'S DISEASE. <i>Innovation in Aging</i> , 2019, 3, S943-S943.	0.0	0
200	Migraine progression in subgroups of migraine based on comorbidities. <i>Neurology</i> , 2019, 93, e2224-e2236.	1.5	60
201	Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1887.	3.8	193
202	Ubrogepant for the Treatment of Migraine. <i>New England Journal of Medicine</i> , 2019, 381, 2230-2241.	13.9	230
203	Migraine Progression: A Systematic Review. <i>Headache</i> , 2019, 59, 306-338.	1.8	198
204	Subtypes Based on Neuropsychological Performance Predict Incident Dementia: Findings from the Rush Memory and Aging Project. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 125-135.	1.2	13
205	Depressive Symptoms Predict Incident Dementia in a Community Sample of Older Adults: Results From the Einstein Aging Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2019, 32, 97-103.	1.2	36
206	Visual memory tests enhance the identification of amnesic MCI cases at greater risk of Alzheimer's disease. <i>International Psychogeriatrics</i> , 2019, 31, 997-1006.	0.6	7
207	Sleep Disorders Among People With Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i> , 2019, 59, 32-45.	1.8	63
208	Barriers to Behavioral Treatment Adherence for Headache: An Examination of Attitudes, Beliefs, and Psychiatric Factors. <i>Headache</i> , 2019, 59, 19-31.	1.8	40
209	Costs of Acute Headache Medication Use and Productivity Losses Among Patients with Migraine: Insights from Three Randomized Controlled Trials. <i>Pharmacoeconomics - Open</i> , 2019, 3, 411-417.	0.9	25
210	The Association of Changes in Pain Acceptance and Headache-Related Disability. <i>Annals of Behavioral Medicine</i> , 2019, 53, 686-690.	1.7	8
211	Repeated Spiral Drawings in Essential Tremor: a Possible Limb-Based Measure of Motor Learning. <i>Cerebellum</i> , 2019, 18, 178-187.	1.4	3
212	Gray matter volume covariance patterns associated with gait speed in older adults: a multi-cohort MRI study. <i>Brain Imaging and Behavior</i> , 2019, 13, 446-460.	1.1	38
213	Abstract P349: Psychosocial Resources and Stressors Associated With Cognition Among Middle-Aged and Older Hispanics/Latinos: Hispanic Community Health Study/Study of Latinos Sociocultural Ancillary Study. <i>Circulation</i> , 2019, 139, .	1.6	0
214	Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. <i>Cephalalgia</i> , 2018, 38, 815-832.	1.8	245
215	A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). <i>Cephalalgia</i> , 2018, 38, 1038-1048.	1.8	113
216	Memory Binding Test Predicts Incident Dementia: Results from the Einstein Aging Study. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 293-304.	1.2	19

#	ARTICLE	IF	CITATIONS
217	Recalled early life adversity and pain: the role of mood, sleep, optimism, and control. <i>Journal of Behavioral Medicine</i> , 2018, 41, 504-515.	1.1	12
218	Re: Placebo responses in device studies. <i>Cephalalgia</i> , 2018, 38, 1007-1008.	1.8	1
219	Identification of Heterogeneous Cognitive Subgroups in Community-Dwelling Older Adults: A Latent Class Analysis of the Einstein Aging Study. <i>Journal of the International Neuropsychological Society</i> , 2018, 24, 511-523.	1.2	17
220	Adolescent Perspectives on the Burden of a Parent's Migraine: Results from the CaMEO Study. <i>Headache</i> , 2018, 58, 512-524.	1.8	16
221	Walking While Talking and Risk of Incident Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, 580-588.	0.6	28
222	Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. <i>Journal of Medical Economics</i> , 2018, 21, 666-675.	1.0	36
223	Reliability and Validity of Ambulatory Cognitive Assessments. <i>Assessment</i> , 2018, 25, 14-30.	1.9	177
224	Behavioral Weight Loss Intervention for Migraine: A Randomized Controlled Trial. <i>Obesity</i> , 2018, 26, 81-87.	1.5	43
225	Pain worsening with physical activity during migraine attacks in women with overweight/obesity: A prospective evaluation of frequency, consistency, and correlates. <i>Cephalalgia</i> , 2018, 38, 1707-1715.	1.8	12
226	Distinct inflammatory response patterns are evident among men and women with higher depressive symptoms. <i>Physiology and Behavior</i> , 2018, 184, 108-115.	1.0	25
227	P3â€467: PROCESS OF IDENTIFYING A CLINICAL MODEL OF LATENT NEUROPSYCHOLOGICAL PROFILES IN COMMUNITYâ€DWELLING OLDER ADULTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1298.	0.4	1
228	P3â€555: HEALTHâ€RELATED QUALITY OF LIFE MEASURES FROM SFâ€36 HEALTH SURVEY PREDICT INCIDENT DEMENTIA IN OLDER ADULTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1335.	0.4	0
229	P4â€163: HEALTH CARE COSTS AMONG NEWLY DIAGNOSED ALZHEIMER'S DISEASE PATIENTS IN A REALâ€WORLD ADMINISTRATIVE CLAIMS DATABASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1501.	0.4	0
230	P2â€598: THE RELATIVE FREQUENCY OF DEMENTIAâ€RELATED DIAGNOSES AMONG INCIDENT ALZHEIMER'S DISEASE PATIENTS COMPARED WITH CONTROLS IN COMMERCIAL AND MEDICARE SUPPLEMENTAL DATABASES. <i>Alzheimer's and Dementia</i> , 2018, 14, P967.	0.4	0
231	P3â€337: GENDER EFFECTS ON GRAY MATTER NETWORKS ASSOCIATED WITH THE MOTORIC COGNITIVE RISK SYNDROME: A MULTIâ€COHORT MRI STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1211.	0.4	0
232	P1â€510: RETRIEVAL SPEED CAN PREDICT MILD COGNITIVE IMPAIRMENT PRIOR TO DIAGNOSIS: RESULTS FROM THE EINSTEIN AGING STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P526.	0.4	0
233	P4â€154: DEPRESSIVE SYMPTOMS PREDICT INCIDENT DEMENTIA IN A COMMUNITY SAMPLE OF OLDER ADULTS: RESULTS FROM THE EINSTEIN AGING STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1498.	0.4	0
234	P1â€315: PREVALENCE OF DIAGNOSED SYMPTOMS PRECEDING ALZHEIMER'S DISEASE DIAGNOSIS AMONG TREATED AND UNTREATED ALZHEIMER'S DISEASE PATIENTS WITH COMMERCIAL AND MEDICARE SUPPLEMENTAL INSURANCE. <i>Alzheimer's and Dementia</i> , 2018, 14, P412.	0.4	0

#	ARTICLE	IF	CITATIONS
235	P4â€119: COGNITIVE PROFILES IN OLD AGE IN RELATION TO INCIDENT ALLâ€CAUSE DEMENTIA AND ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1484.	0.4	0
236	P2â€493: RETRIEVAL SPEED AND LEVEL OF PERFORMANCE ON THE CUEDâ€RECALL RETRIEVAL SPEED TASK CAN PREDICT ONSET OF COGNITIVE IMPAIRMENT: RESULTS FROM THE EINSTEIN AGING STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P918.	0.4	0
237	Class-Specific Incidence of All-Cause Dementia and Alzheimerâ€™s Disease: A Latent Class Approach. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 347-357.	1.2	13
238	Subjective Cognitive Decline Prediction of Mortality: Results from the Einstein Aging Study. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 239-248.	1.2	4
239	Improving Medical Communication in Migraine Management: A Modified Delphi Study to Develop a Digital Migraine Tracker. <i>Headache</i> , 2018, 58, 1358-1372.	1.8	25
240	P2â€609: MOTORIC COGNITIVE RISK SYNDROME: A GAIT OR COGNITIVE SYNDROME?. <i>Alzheimer's and Dementia</i> , 2018, 14, P972.	0.4	2
241	Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences. <i>Headache</i> , 2018, 58, 1408-1426.	1.8	106
242	Negative and positive affect as predictors of inflammation: Timing matters. <i>Brain, Behavior, and Immunity</i> , 2018, 74, 222-230.	2.0	42
243	American Headache Society Survey About Urgent and Emergency Management of Headache Patients. <i>Headache</i> , 2018, 58, 1389-1396.	1.8	8
244	MRI-defined White Matter Microstructural Alteration Associated with Soccer Heading Is More Extensive in Women than Men. <i>Radiology</i> , 2018, 289, 478-486.	3.6	46
245	Qualitative Change in Migraine Prevention?. <i>Headache</i> , 2018, 58, 1092-1095.	1.8	7
246	Apathy and depressive symptoms in older people and incident myocardial infarction, stroke, and mortality: a systematic review and meta-analysis of individual participant data. <i>Clinical Epidemiology</i> , 2018, Volume 10, 363-379.	1.5	49
247	Heading Frequency Is More Strongly Related to Cognitive Performance Than Unintentional Head Impacts in Amateur Soccer Players. <i>Frontiers in Neurology</i> , 2018, 9, 240.	1.1	38
248	Measures of Functioning in Patients With Episodic Migraine: Findings From a Doubleâ€Blind, Randomized, Placeboâ€Controlled Phase 2b Trial With Galcanezumab. <i>Headache</i> , 2018, 58, 1225-1235.	1.8	21
249	Fremanezumab for preventive treatment of migraine. <i>Neurology</i> , 2018, 91, e1152-e1165.	1.5	40
250	Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. <i>Journal of Headache and Pain</i> , 2018, 19, 38.	2.5	88
251	Factors Related to Migraine Patientsâ€™ Decisions to Initiate Behavioral Migraine Treatment Following a Headache Specialistâ€™s Recommendation: A Prospective Observational Study. <i>Pain Medicine</i> , 2018, 19, 2274-2282.	0.9	29
252	DFNâ€02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Doubleâ€Blind, Placeboâ€Controlled Study. <i>Headache</i> , 2018, 58, 676-687.	1.8	31

#	ARTICLE	IF	CITATIONS
253	Comment: Noninvasive neurostimulation for migraine should be part of the general neurologist's therapeutic armamentarium. <i>Neurology</i> , 2018, 91, 167-167.	1.5	1
254	Association of psychological, cognitive, and functional variables with self-reported executive functioning in a sample of nondemented community-dwelling older adults. <i>Applied Neuropsychology Adult</i> , 2017, 24, 364-375.	0.7	31
255	Transcutaneous and Percutaneous Neurostimulation for Headache Disorders. <i>Headache</i> , 2017, 57, 4-13.	1.8	17
256	Psychological Factors Associated With Chronic Migraine and Severe Migraine-Related Disability: An Observational Study in a Tertiary Headache Center. <i>Headache</i> , 2017, 57, 593-604.	1.8	71
257	A dedicated scholarly research program in an adult and pediatric neurology residency program. <i>Neurology</i> , 2017, 88, 1366-1370.	1.5	15
258	Spatial navigation and risk of cognitive impairment: A prospective cohort study. <i>Alzheimer's and Dementia</i> , 2017, 13, 985-992.	0.4	32
259	Characterization of Neck Strength in Healthy Young Adults. <i>PM and R</i> , 2017, 9, 884-891.	0.9	22
260	Family Impact of Migraine: Development of the Impact of Migraine on Partners and Adolescent Children (IMPAC) Scale. <i>Headache</i> , 2017, 57, 570-585.	1.8	30
261	Post Hoc Subanalysis of Two Randomized, Controlled Phase 3 Trials Evaluating Diclofenac Potassium for Oral Solution: Impact of Migraine-Associated Nausea and Prior Triptan Use on Efficacy. <i>Headache</i> , 2017, 57, 756-765.	1.8	3
262	Association Between Vascular Pathology and Rate of Cognitive Decline Independent of Alzheimer's Disease Pathology. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 1836-1841.	1.3	15
263	[ICâ€â€127]: GRAY MATTER VOLUME AND THE MOTORIC COGNITIVE RISK SYNDROME: A MULTIâ€COHORT MRI STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P96.	0.4	1
264	Association Between Obesity and Migraine in Women. <i>Current Pain and Headache Reports</i> , 2017, 21, 41.	1.3	33
265	Trends in Dementia Incidence in a Birth Cohort Analysis of the Einstein Aging Study. <i>JAMA Neurology</i> , 2017, 74, 1345.	4.5	73
266	Personality predicts mortality risk: An integrative data analysis of 15 international longitudinal studies. <i>Journal of Research in Personality</i> , 2017, 70, 174-186.	0.9	155
267	Rare coding variants in <i>PLCG2</i> , <i>ABI3</i> , and <i>TREM2</i> implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	9.4	783
268	Caffeine in the management of patients with headache. <i>Journal of Headache and Pain</i> , 2017, 18, 107.	2.5	73
269	Evaluation of the Reliability, Validity, and Predictive Validity of the Subscales of the Perceived Stress Scale in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 987-996.	1.2	25
270	Comorbid pain and migraine chronicity. <i>Neurology</i> , 2017, 89, 461-468.	1.5	61

#	ARTICLE	IF	CITATIONS
271	Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study. <i>Headache</i> , 2017, 57, 1026-1040.	1.8	49
272	Cognitive and motor functioning in elderly glucocerebrosidase mutation carriers. <i>Neurobiology of Aging</i> , 2017, 58, 239.e1-239.e7.	1.5	6
273	Growth of Headache Research: A 1983â€“2014 bibliometric study. <i>Cephalalgia</i> , 2017, 37, 1299-1309.	1.8	19
274	Sex Differences in the Relationship between Depressive Symptoms and Risk of Amnesic Mild Cognitive Impairment. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 13-22.	0.6	34
275	Memory Binding Test Distinguishes Amnesic Mild Cognitive Impairment and Dementia from Cognitively Normal Elderly. <i>Archives of Clinical Neuropsychology</i> , 2017, 32, 29-39.	0.3	33
276	Roles of hippocampal subfields in verbal and visual episodic memory. <i>Behavioural Brain Research</i> , 2017, 317, 157-162.	1.2	78
277	[P3â€“355]: WHITE MATTER HYPERINTENSITIES MODIFY THE RELATIONSHIP BETWEEN HIPPOCAMPAL VOLUME AND VERBAL MEMORY IN OLDER ADULTS WITHOUT DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P1091.	0.4	0
278	[P1â€“323]: SUBJECTIVE COGNITIVE DECLINE (SCD) PREDICTS MORTALITY IN A COMMUNITYâ€“BASED ELDERLY COHORT: RESULTS FROM THE EINSTEIN AGING STUDY (EAS). <i>Alzheimer's and Dementia</i> , 2017, 13, P379.	0.4	0
279	Expertsâ€™ opinion about the primary headache diagnostic criteria of the ICHD-3rd edition beta in children and adolescents. <i>Journal of Headache and Pain</i> , 2017, 18, 109.	2.5	47
280	Expertsâ€™ opinion about the pediatric secondary headaches diagnostic criteria of the ICHD-3 beta. <i>Journal of Headache and Pain</i> , 2017, 18, 113.	2.5	24
281	Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. <i>Journal of Headache and Pain</i> , 2017, 18, 101.	2.5	158
282	[P2â€“466]: EFFECT OF THE APOLIPOPROTEIN E E2 (APOE2) ALLELE ON MEMORY DECLINE AND INCIDENCE AND TRANSITION TO ALZHEIMER'S DISEASE (AD): RESULTS FROM THE EINSTEIN AGING STUDY (EAS). <i>Alzheimer's and Dementia</i> , 2017, 13, P819.	0.4	0
283	Positively Worded Subscale Score of the Perceived Stress Scale Is Associated with Cognitive Domain Function. <i>Journal of Behavioral and Brain Science</i> , 2017, 07, 311-324.	0.2	12
284	Age-related cognitive decline and associations with sex, education and apolipoprotein E genotype across ethnocultural groups and geographic regions: a collaborative cohort study. <i>PLoS Medicine</i> , 2017, 14, e1002261.	3.9	120
285	The association of visual memory with hippocampal volume. <i>PLoS ONE</i> , 2017, 12, e0187851.	1.1	12
286	A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. <i>Cephalalgia</i> , 2016, 36, 887-898.	1.8	218
287	A migraine management training program for primary care providers: An overview of a survey and pilot study findings, lessons learned, and considerations for further research. <i>Headache</i> , 2016, 56, 725-740.	1.8	38
288	The migraine postdrome. <i>Neurology</i> , 2016, 87, 309-313.	1.5	134

#	ARTICLE	IF	CITATIONS
289	Aerobic Exercise for Reducing Migraine Burden: Mechanisms, Markers, and Models of Change Processes. <i>Headache</i> , 2016, 56, 357-369.	1.8	90
290	How Well Does the ICHD 3 (Beta) Help in Real-Life Migraine Diagnosis and Management?. <i>Current Pain and Headache Reports</i> , 2016, 20, 66.	1.3	10
291	Motoric Cognitive Risk Syndrome and Falls Risk: A Multi-Center Study. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1043-1052.	1.2	77
292	Memory Binding Test Predicts Incident Amnestic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1585-1595.	1.2	23
293	P1-362: Longitudinal Analysis of The Free and Cued Selective Reminding Test in Pre-Clinical and Clinical Alzheimer's Disease: Temporal Unfolding of Stages of Memory Impairment. , 2016, 12, P568-P569.		1
294	P4-235: Cognitive Decline and Effects of Sex, Education and Apolipoprotein E Genotype on Cognitive Performance in Diverse Ethno-Cultural and Geographical Regions Internationally: The Cosmic Collaboration. <i>Alzheimer's and Dementia</i> , 2016, 12, P1119.	0.4	1
295	P4-363: Intensive Ambulatory Assessments are Feasible in Community Dwelling Adults Aged 70+: Results From the Einstein Aging Study (EAS). , 2016, 12, P1176-P1176.		0
296	Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEO Study. <i>Mayo Clinic Proceedings</i> , 2016, 91, 596-611.	1.4	123
297	Electronic behavioral interventions for headache: a systematic review. <i>Journal of Headache and Pain</i> , 2016, 17, 51.	2.5	52
298	Cholesteryl ester transfer protein genotype modifies the effect of apolipoprotein μ 4 on memory decline in older adults. <i>Neurobiology of Aging</i> , 2016, 41, 200.e7-200.e12.	1.5	9
299	Glycemic control, cognitive function, and family support among middle-aged and older Hispanics with diabetes: The Hispanic Community Health Study/Study of Latinos. <i>Diabetes Research and Clinical Practice</i> , 2016, 117, 64-73.	1.1	19
300	Cerebral Hemodynamics in the Elderly. <i>Journal of Ultrasound in Medicine</i> , 2016, 35, 1907-1914.	0.8	35
301	Nativity differences in allostatic load by age, sex, and Hispanic background from the Hispanic Community Health Study/Study of Latinos. <i>SSM - Population Health</i> , 2016, 2, 416-424.	1.3	36
302	Predicting Inadequate Response to Acute Migraine Medication: Results From the <sc>A</sc>merican Migraine Prevalence and Prevention (<sc>AMPP</sc>) Study. <i>Headache</i> , 2016, 56, 1635-1648.	1.8	64
303	Bidirectional Changes in Anisotropy Are Associated with Outcomes in Mild Traumatic Brain Injury. <i>American Journal of Neuroradiology</i> , 2016, 37, 1983-1991.	1.2	21
304	Female advantage in verbal memory. <i>Neurology</i> , 2016, 87, 1916-1924.	1.5	163
305	A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability. <i>Headache</i> , 2016, 56, 1280-1289.	1.8	127
306	Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i> , 2016, 56, 821-834.	1.8	160

#	ARTICLE	IF	CITATIONS
307	Abdominal obesity is a risk factor for dysexecutive function in chronic kidney disease. Preventive Medicine Reports, 2016, 4, 128-133.	0.8	4
308	Differential association of left and right hippocampal volumes with verbal episodic and spatial memory in older adults. Neuropsychologia, 2016, 93, 380-385.	0.7	108
309	Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series. Journal of Headache and Pain, 2016, 17, 106.	2.5	45
310	2015 <i>Headache</i> Membersâ€™™ Choice Award. Headache, 2016, 56, 1088-1090.	1.8	0
311	A Brief Dietary Assessment Predicts Executive Dysfunction in an Elderly Cohort: Results from the Einstein Aging Study. Journal of the American Geriatrics Society, 2016, 64, e131-e136.	1.3	11
312	OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program. Cephalalgia, 2016, 36, 899-908.	1.8	66
313	Pain grade and sleep disturbance in older adults: evaluation the role of pain, and stress for depressed and nonâ€™depressed individuals. International Journal of Geriatric Psychiatry, 2016, 31, 450-457.	1.3	19
314	Regional versus general anaesthesia for improved cognitive function after procedures other than cardiac surgery or neurosurgery in adult and paediatric patients. The Cochrane Library, 2016, 2016, .	1.5	3
315	Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM). Cephalalgia, 2016, 36, 203-215.	1.8	42
316	Better verbal memory in women than men in MCI despite similar levels of hippocampal atrophy. Neurology, 2016, 86, 1368-1376.	1.5	131
317	Social Support Buffers the Impact of Depressive Symptoms on Life Satisfaction in Old Age. Clinical Gerontologist, 2016, 39, 139-157.	1.2	48
318	Metabolic Syndrome and Smoking Are Associated with Future Development of Advanced Chronic Kidney Disease in Older Adults. CardioRenal Medicine, 2016, 6, 108-115.	0.7	8
319	Migraine and its psychiatric comorbidities. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 741-749.	0.9	298
320	Hippocampal volume and cingulum bundle fractional anisotropy are independently associated with verbal memory in older adults. Brain Imaging and Behavior, 2016, 10, 652-659.	1.1	66
321	Perceived Stress Is Differentially Related to Hippocampal Subfield Volumes among Older Adults. PLoS ONE, 2016, 11, e0154530.	1.1	48
322	P3-181: Correlates of memory function in older adults: The importance of white matter hyperintensities and hippocampal volume. , 2015, 11, P699-P700.		0
323	P3-111: Abdominal obesity is a risk factor for executive dysfunction in chronic kidney disease but not in otherwise healthy older adults. , 2015, 11, P663-P663.		0
324	P3-259: A brief dietary assessment predicts executive dysfunction in an elderly cohort: Results from the einstein aging study (EAS). , 2015, 11, P731-P732.		1

#	ARTICLE	IF	CITATIONS
325	P4-104: Cross-sectional diagnostic validity of the memory binding test. , 2015, 11, P815-P816.		0
326	P3-118: Perceived stress, ApoE status, and risk of amnesic mild cognitive impairment (aMCI): Results from the einstein aging study (EAS). , 2015, 11, P667-P667.		0
327	O3-02-03: Is dementia incidence declining? a birth cohort analysis of the einstein aging study (EAS) cohort, 1993-2014. , 2015, 11, P220-P220.		0
328	P2-200: Identifying memory impairment and dementia in primary care settings. , 2015, 11, P569-P569.		0
329	Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (<sc>AMPP</sc>) Study. Headache, 2015, 55, 825-839.	1.8	20
330	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. Journal of Alzheimer's Disease, 2015, 48, S63-S86.	1.2	317
331	Reference Data of the Spanish Memory Binding Test in a Midlife Population from the ALFA STUDY (Alzheimer's and Family). Journal of Alzheimer's Disease, 2015, 48, 613-625.	1.2	18
332	Sumatriptan Iontophoretic Transdermal System Reduces Treatment-Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline " Results From a Randomized Controlled Trial. Headache, 2015, 55, 1124-1132.	1.8	7
333	Chronic Kidney Disease in Non-Diabetic Older Adults: Associated Roles of the Metabolic Syndrome, Inflammation, and Insulin Resistance. PLoS ONE, 2015, 10, e0139369.	1.1	27
334	The Prevalence of Mild Cognitive Impairment in Diverse Geographical and Ethnocultural Regions: The COSMIC Collaboration. PLoS ONE, 2015, 10, e0142388.	1.1	225
335	Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety. International Journal of General Medicine, 2015, 8, 79.	0.8	51
336	Burden of migraine related to menses: results from the AMPP study. Journal of Headache and Pain, 2015, 16, 24.	2.5	60
337	Recalled maltreatment, migraine, and tension-type headache. Neurology, 2015, 84, 132-140.	1.5	66
338	Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 996-1001.	0.9	105
339	Primary headache: What's stress got to do with it?. Cephalalgia, 2015, 35, 844-849.	1.8	7
340	O3-10-04: Performance on the memory binding test predicts incident aMCI and dementia: Results from the einstein aging study. , 2015, 11, P242-P242.		0
341	P3-213: Estimating episodic memory within-subject decline among nondemented older adults: Results from the einstein aging study (EAS). , 2015, 11, P714-P714.		2
342	P4-149: Stress and white matter hyperintensities in nondemented older adults. , 2015, 11, P836-P836.		0

#	ARTICLE	IF	CITATIONS
343	P1-022: Coping and distress and risk of amnesic mild cognitive impairment in older adults. , 2015, 11, P344-P345.		0
344	Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention. Headache, 2015, 55, 103-122.	1.8	227
345	Assessing Clinically Meaningful Treatment Effects in Controlled Trials: Chronic Migraine as an Example. Journal of Pain, 2015, 16, 164-175.	0.7	49
346	Neurocognitive Function Among Middle-aged and Older Hispanic/Latinos: Results from the Hispanic Community Health Study/Study of Latinos. Archives of Clinical Neuropsychology, 2015, 30, 68-77.	0.3	84
347	Exploring the impact of comorbid primary headaches and neck pain. Scandinavian Journal of Pain, 2015, 8, 23-24.	0.5	0
348	Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology, 2015, 84, 688-695.	1.5	219
349	The Effects of Stress on Cognitive Aging, Physiology and Emotion (ESCAPE) Project. BMC Psychiatry, 2015, 15, 146.	1.1	120
350	Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurology, The, 2015, 14, 1091-1100.	4.9	221
351	Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurology, The, 2015, 14, 1081-1090.	4.9	236
352	Comparison of "Word" vs. "Picture" version of the Free and Cued Selective Reminding Test (FCSRT) in older adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 94-100.	1.2	27
353	Acute headache diagnosis in pregnant women. Neurology, 2015, 85, 1024-1030.	1.5	78
354	Prevalence of neck pain in migraine and tension-type headache: A population study. Cephalalgia, 2015, 35, 211-219.	1.8	235
355	The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia, 2015, 35, 563-578.	1.8	203
356	Methodological Issues in Studying Trigger Factors and Premonitory Features of Migraine. Headache, 2014, 54, 1661-1669.	1.8	84
357	Reliability and Validity of the Migraine Disability Assessment Scale among Migraine and Tension Type Headache in Iranian Patients. BioMed Research International, 2014, 2014, 1-7.	0.9	30
358	Reduction in perceived stress as a migraine trigger. Neurology, 2014, 82, 1395-1401.	1.5	123
359	Eager for better migraine therapies. Neurology, 2014, 83, 954-955.	1.5	1
360	Motoric cognitive risk syndrome. Neurology, 2014, 83, 2278-2284.	1.5	133

#	ARTICLE	IF	CITATIONS
361	Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. <i>Lancet Neurology</i> , The, 2014, 13, 1100-1107.	4.9	333
362	Improving the Classification of Migraine Subtypes: An Empirical Approach Based on Factor Mixture Models in the <sc>A</sc>merican <sc>M</sc>igraine <sc>P</sc>revalence and <sc>P</sc>revention (<sc>AMPP</sc>) Study. <i>Headache</i> , 2014, 54, 830-849.	1.8	32
363	Hippocampal subfields differentially correlate with chronic pain in older adults. <i>Brain Research</i> , 2014, 1573, 54-62.	1.1	35
364	P3-152: PAIN INTENSITY AND PAIN INTERFERENCE ARE ASSOCIATED WITH TRANSITIONS FROM COGNITIVE NORMALITY, AMNESTIC MCI (AMCI), AND DEMENTIA: RESULTS FROM THE EINSTEIN AGING STUDY (EAS). , 2014, 10, P684-P684.		0
365	P3-156: POOR RENAL FUNCTION IS ASSOCIATED WITH AMCI AT CROSS-SECTION: RESULTS FROM THE EINSTEIN AGING STUDY. , 2014, 10, P685-P686.		0
366	P3-167: PERCEIVED STRESS, PERSONALITY, AND RISK OF AMNESTIC MILD COGNITIVE IMPAIRMENT (AMCI): RESULTS FROM THE EINSTEIN AGING STUDY (EAS). , 2014, 10, P690-P690.		0
367	P2-314: PERCEIVED STRESS AND RISK OF DEMENTIA IN OLDER ADULTS WITH AMNESTIC MILD COGNITIVE IMPAIRMENT. , 2014, 10, P594-P594.		3
368	Methodological Issues in Studying Rates and Predictors of Migraine Progression and Remission. <i>Headache</i> , 2013, 53, 930-934.	1.8	18
369	Rates and reasons for discontinuation of triptans and opioids in episodic migraine: Results from the American Migraine Prevalence and Prevention (AMPP) study. <i>Journal of the Neurological Sciences</i> , 2013, 326, 10-17.	0.3	33
370	Barriers to the Diagnosis and Treatment of Migraine: Effects of Sex, Income, and Headache Features. <i>Headache</i> , 2013, 53, 81-92.	1.8	144
371	Frequency and Burden of Headache-Related Nausea: Results From the <sc>A</sc>merican <sc>M</sc>igraine <sc>P</sc>revalence and <sc>P</sc>revention (<sc>AMPP</sc>) Study. <i>Headache</i> , 2013, 53, 93-103.	1.8	59
372	Healthcare resource utilization and direct costs associated with frequent nausea in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. <i>Journal of Medical Economics</i> , 2013, 16, 490-499.	1.0	13
373	Examination of Unmet Treatment Needs Among Persons With Episodic Migraine: Results of the <sc>A</sc>merican <sc>M</sc>igraine <sc>P</sc>revalence and <sc>P</sc>revention (<sc>AMPP</sc>) Study. <i>Headache</i> , 2013, 53, 1300-1311.	1.8	128
374	Depression and risk of transformation of episodic to chronic migraine. <i>Journal of Headache and Pain</i> , 2012, 13, 615-624.	2.5	214
375	Headache Impact of Chronic and Episodic Migraine: Results From the American Migraine Prevalence and Prevention Study. <i>Headache</i> , 2012, 52, 3-17.	1.8	174
376	Opioid Use and Dependence Among Persons With Migraine: Results of the AMPP Study. <i>Headache</i> , 2012, 52, 18-36.	1.8	103
377	Abstract 2292: Dipyridamole Induced Headache Indicates Lower Recurrence Risk in Secondary Prevention of Ischemic Stroke. <i>Stroke</i> , 2012, 43, .	1.0	0
378	Progress in headache mechanisms and management. <i>Nature Reviews Neurology</i> , 2011, 7, 67-68.	4.9	5

#	ARTICLE	IF	CITATIONS
379	Combined prophylactic \hat{A} -blocker and behavioural migraine management improves 30-day migraine outcomes compared with either strategy alone, or optimised acute treatment only. Evidence-Based Medicine, 2011, 16, 77-78.	0.6	0
380	Modifiable predictors of racial differences in gait velocity in an elderly urban cohort. Annals of the Rheumatic Diseases, 2011, 70, A93-A93.	0.5	0
381	Topiramate intervention to prevent transformation of episodic migraine: The topiramate INTREPID study. Cephalalgia, 2011, 31, 18-30.	1.8	53
382	Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurology, The, 2010, 9, 373-380.	4.9	413
383	Transcranial Magnetic Simulation in the Treatment of Migraine. Neurotherapeutics, 2010, 7, 204-212.	2.1	139
384	Response: Coexisting Trigeminal Autonomic Cephalalgias and Hemicrania Continua. Headache, 2010, 50, 1218-1219.	1.8	1
385	Exceptional Parental Longevity Associated with Lower Risk of Alzheimer's Disease and Memory Decline. Journal of the American Geriatrics Society, 2010, 58, 1043-1049.	1.3	48
386	Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: Results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia, 2010, 30, 1336-1345.	1.8	51
387	The social impact and burden of headache. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 23-32.	1.0	4
388	Overuse of acute migraine medications and migraine chronification. Current Pain and Headache Reports, 2009, 13, 301-307.	1.3	109
389	Migraine in the Triptan Era: Lessons From Epidemiology, Pathophysiology, and Clinical Science. Headache, 2009, 49, S21-S33.	1.8	47
390	Moving Forward " Essential Questions for the Next 10 Years. Headache, 2009, 49, S43-6.	1.8	3
391	Tracing transformation. Neurology, 2009, 72, S3-7.	1.5	161
392	Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ: British Medical Journal, 2009, 339, b3914-b3914.	2.4	648
393	Predicting Seizures: A Behavioral Approach. Neurologic Clinics, 2009, 27, 925-940.	0.8	16
394	Conceptualizing the relationship between chronic migraine and episodic migraine. Expert Review of Neurotherapeutics, 2009, 9, 1451-1454.	1.4	16
395	Introduction to the Special Series on the Chronification of Headache: Mechanisms, Risk Factors, and Behavioral Strategies Aimed at Primary and Secondary Prevention of Chronic Headache. Headache, 2008, 48, 5-6.	1.8	13
396	Looking to the Future: Research Designs for Study of Headache Disease Progression. Headache, 2008, 48, 58-66.	1.8	23

#	ARTICLE	IF	CITATIONS
397	In-office Discussions of Migraine: Results from the American Migraine Communication Study. <i>Journal of General Internal Medicine</i> , 2008, 23, 1145-1151.	1.3	57
398	Cutaneous allodynia in the migraine population. <i>Annals of Neurology</i> , 2008, 63, 148-158.	2.8	461
399	Headache as a Real Disease. <i>Headache</i> , 2008, 48, 707-710.	1.8	4
400	Toward an Epidemiology of Refractory Migraine: Current Knowledge and Issues for Future Research. <i>Headache</i> , 2008, 48, 791-798.	1.8	20
401	Acute Migraine Medications and Evolution From Episodic to Chronic Migraine: A Longitudinal Population-Based Study. <i>Headache</i> , 2008, 48, 1157-1168.	1.8	683
402	Excessive acute migraine medication use and migraine progression. <i>Neurology</i> , 2008, 71, 1821-1828.	1.5	244
403	Clinical course in migraine. <i>Neurology</i> , 2008, 71, 848-855.	1.5	190
404	Migraine and cardiovascular disease: is there a link?. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 74-75.	2.7	5
405	Ten Lessons on the Epidemiology of Migraine. <i>Headache</i> , 2007, 47, S2-S9.	1.8	78
406	How useful is the HIT-6,¢ for measuring headache-related disability?. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 70-71.	2.7	10
407	Age-dependent prevalence and clinical features of migraine. <i>Neurology</i> , 2006, 67, 246-251.	1.5	216
408	The epidemiology of migraine. <i>The American Journal of Medicine: Supplement</i> , 2005, 118, 3-10.	1.7	115
409	Aspirin Is Efficacious for the Treatment of Acute Migraine. <i>Headache</i> , 2005, 45, 283-292.	1.8	80
410	Headache: triumphs in translational research. <i>Lancet Neurology</i> , The, 2005, 4, 11-12.	4.9	5
411	ASSESSMENT OF COGNITIVE FUNCTION OF THE ELDERLY POPULATION: EFFECTS OF DARIFENACIN. <i>Journal of Urology</i> , 2005, 173, 493-498.	0.2	169
412	Migraine: primary care challenges in diagnosis and treatment. Introduction. <i>American Journal of Medicine</i> , 2005, 118 Suppl 1, 1S-2S.	0.6	0
413	CGRP antagonists in the acute treatment of migraine. <i>Lancet Neurology</i> , The, 2004, 3, 332.	4.9	11
414	The global burden of migraine. <i>Journal of Headache and Pain</i> , 2003, 4, s3-s11.	2.5	16

#	ARTICLE	IF	CITATIONS
415	Assessment of Migraine Disability Using the Migraine Disability Assessment (MIDAS) Questionnaire: A Comparison of Chronic Migraine With Episodic Migraine. <i>Headache</i> , 2003, 43, 336-342.	1.8	218
416	Screening for Dementia by Telephone Using the Memory Impairment Screen. <i>Journal of the American Geriatrics Society</i> , 2003, 51, 1382-1390.	1.3	208
417	Disease Management of Migraine and the Importance of Stratified Care. <i>Disease Management and Health Outcomes</i> , 2003, 11, 379-388.	0.3	1
418	Assessing disability using the migraine disability assessment questionnaire. <i>Expert Review of Neurotherapeutics</i> , 2003, 3, 317-325.	1.4	7
419	Chronic daily headache. , 2002, , 955-972.		0
420	What Do Patients With Migraine Want From Acute Migraine Treatment?. <i>Headache</i> , 2002, 42, 3-9.	1.8	214
421	Epidemiology of migraine. <i>Current Pain and Headache Reports</i> , 2001, 5, 189-194.	1.3	13
422	Effect of Rizatriptan and Other Triptans on the Nausea Symptom of Migraine: A Post Hoc Analysis. <i>Headache</i> , 2001, 41, 754-763.	1.8	38
423	Migraine Diagnosis and Treatment: Results From the American Migraine Study II. <i>Headache</i> , 2001, 41, 638-645.	1.8	631
424	Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II. <i>Headache</i> , 2001, 41, 646-657.	1.8	1,933
425	Information About Migraine Disability Influences Physicians' Perceptions of Illness Severity and Treatment Needs. <i>Headache</i> , 2001, 41, 343-350.	1.8	282
426	Estimation of bivariate measurements having different change points, with application to cognitive ageing. <i>Statistics in Medicine</i> , 2001, 20, 3695-3714.	0.8	77
427	Migraine MLTâ€œDown: An Unusual Presentation of Migraine in Patients With Aspartameâ€œTriggered Headaches. <i>Headache</i> , 2001, 41, 899-901.	1.8	30
428	Epidemiology and Economic Impact of Migraine. <i>Current Medical Research and Opinion</i> , 2001, 17, s4-12.	0.9	102
429	A change point model for estimating the onset of cognitive decline in preclinical Alzheimer's disease. , 2000, 19, 1555-1566.		188
430	Stratified Care vs Step Care Strategies for Migraine. <i>JAMA - Journal of the American Medical Association</i> , 2000, 284, 2599.	3.8	318
431	Comparison of motor conduction abnormalities in lumbosacral radiculopathy and axonal polyneuropathy. , 1999, 22, 1053-1057.		24
432	Migraine: A â€œWoman's Disease?â€œ <i>Women and Health</i> , 1999, 28, 79-99.	0.4	7

#	ARTICLE	IF	CITATIONS
433	Medical Consultation for Migraine: Results From the American Migraine Study. <i>Headache</i> , 1998, 38, 87-96.	1.8	340
434	Prevalence of Frequent Headache in a Population Sample. <i>Headache</i> , 1998, 38, 497-506.	1.8	560
435	Headache in the elderly. <i>Journal of Back and Musculoskeletal Rehabilitation</i> , 1998, 11, 3-17.	0.4	1
436	Free and cued selective reminding and selective reminding in the elderly. <i>Journal of Clinical and Experimental Neuropsychology</i> , 1997, 19, 643-654.	0.8	54
437	The effect of dementia risk factors on comparative and diagnostic selective reminding norms. <i>Journal of the International Neuropsychological Society</i> , 1997, 3, 317-326.	1.2	48
438	The Site of Common Side Effects of Sumatriptan. <i>Headache</i> , 1997, 37, 289-290.	1.8	5
439	Sumatriptan Relieves Migrainelike Headaches Associated With Carbon Monoxide Exposure. <i>Headache</i> , 1997, 37, 392-395.	1.8	29
440	Familial risk of migraine: A population-based study. <i>Annals of Neurology</i> , 1997, 41, 166-172.	2.8	137
441	Oscillopsis: An Unusual Auditory Aura in Migraine. <i>Headache</i> , 1995, 35, 428-429.	1.8	11
442	Event-related potential correlates of early processing in normal aging. <i>International Journal of Neuroscience</i> , 1995, 80, 371-382.	0.8	16
443	Ageing, encoding specificity, and memory change in the Double Memory Test. <i>Journal of the International Neuropsychological Society</i> , 1995, 1, 483-493.	1.2	49
444	Classification of Daily and Near-Daily Headaches: Proposed Revisions to the IHS Criteria. <i>Headache</i> , 1994, 34, 1-7.	1.8	382
445	An Update on the Epidemiology of Migraine. <i>Headache</i> , 1994, 34, 319-328.	1.8	167
446	The Burden of Migraine. <i>Pharmacoeconomics</i> , 1994, 6, 215-221.	1.7	62
447	Pathological markers associated with normal aging and dementia in the elderly. <i>Annals of Neurology</i> , 1993, 34, 566-573.	2.8	166
448	Migraine headache: Epidemiology and health care utilization. <i>Cephalalgia</i> , 1993, 13, 41-46.	1.8	67
449	Reliability in headache diagnosis. <i>Cephalalgia</i> , 1993, 13, 29-33.	1.8	41
450	Evaluation of Chronic Daily Headacheâ€”Comparison to Criteria for Chronic Tension-Type Headache. <i>Cephalalgia</i> , 1992, 12, 365-368.	1.8	93

#	ARTICLE	IF	CITATIONS
451	Medication Use and Disability Among Migraineurs: A National Probability Sample Survey. <i>Headache</i> , 1992, 32, 223-228.	1.8	171
452	Myocardial Ischemia Related to Ergot Alkaloids: A Case Report and Literature Review. <i>Headache</i> , 1991, 31, 446-450.	1.8	39
453	Nerve growth factor prevents toxic neuropathy in mice. <i>Annals of Neurology</i> , 1991, 29, 87-90.	2.8	228
454	Arterial Stenosis in Migraine: Spasm or Arteriopathy?. <i>Headache</i> , 1990, 30, 52-61.	1.8	78
455	Spreading Depression Marches On. <i>Headache</i> , 1990, 30, 741-741.	1.8	0
456	Does Scopolamine Directly Impair Memory?. <i>Journal of Cognitive Neuroscience</i> , 1989, 1, 327-335.	1.1	31
457	Headaches in Hospitalized Cocaine Users. <i>Headache</i> , 1989, 29, 225-228.	1.8	28
458	Aspartame as a Dietary Trigger of Headache. <i>Headache</i> , 1989, 29, 90-92.	1.8	70